Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib for Malignant Ascites or Pleural Effusion
NCT01262612Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib in malignant ascites and malignant pleural effusion (MPE) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Puncture Free Survival at 44 days. Started Apr 2010; status: terminated.
02
Drugs
cediranib
03
Conditions
malignant ascitesmalignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT01262612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262612.